| Reference | [1]. Anesth Analg. 1979 May-Jun;58(3):189-94.<br />
Cardiovascular effects of benzquinamide.<br />
Smith DJ, Rushin JM, Urquilla PR, Rhee CW, Yoon HJ, Simpson FA, Srichomkuan T, Lee HS, Knapp RB.<br />
The cardiovascular effects of benzquinamide were evaluated in anesthetized dogs. Intravenous benzquinamide, 0.5 to 5 mg/kg, caused tachycardia, elevated blood norepinephrine levels, frequent ventricular arrhythmias, and brief hypotension. Ganglionic blockade by hexamethonium prior to administration of benzquinamide prevented the tachycardia and alterations in norepinephrine levels but prolonged the period of hypotension. In isolated mesenteric arterial preparations benzquinamide interfered with contractile force generated by potassium chloride, norepinephrine, and prostaglandin F2 alpha. It is concluded that benzquinamide directly relaxes vascular smooth muscle thereby producing in vivo reduced peripheral vascular resistance and hypotension, which are compensated for by reflex sympathetic activation.<br />
PMID: 582237 [Indexed for MEDLINE]<br />
<br />
[2]. Cancer. 1981 Mar 15;47(6):1439-43. doi: 10.1002/1097-0142(19810315)47:6<1439::aid-cncr2820470633>3.0.co;2-#.<br />
Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide.<br />
Neidhart JA, Gagen M, Young D, Wilson HE.<br />
Sixty-four patients receiving cancer chemotherapy known to induce severe emesis entered a randomized double-blind study of the antiemetic efficacy of haloperidol (Haldol) and benzquinamide (Emetecon). Patients preferred haloperidol for control of emesis induced by cis-platinum (78 vs. 22%) or nitrogen mustard (67 vs. 16%). Patients receiving Doxorubicin preferred benzquinamide by a small margin (46 to 38%). Individual patients who experienced no relief with their first antiemetic (13 of 15) usually got some relief with the other after crossover. Haloperidol was more effective than benzquinamide (54 vs. 29%) in patients previously unrelieved by prochlorperazine (Compazine). Complete relief of vomiting was obtained in 14 of 45 patients receiving haloperidol but only five of 41 patients receiving benzquinamide experienced no vomiting, again dependent on the anticancer agent used. Although haloperidol is a more effective antiemetic agent overall, efficacy is related to the anticancer treatment and probably to individual patient characteristics.<br />
DOI: 10.1002/1097-0142(19810315)47:6<1439::aid-cncr2820470633>3.0.co;2-# PMID: 7013968 [Indexed for MEDLINE]<br />
<br />
[3]. Biochem Pharmacol. 1964 Oct;13:1421-35. doi: 10.1016/0006-2952(64)90190-x.<br />
THE DISTRIBUTION, EXCRETION AND METABOLISM OF BENZQUINAMIDE.<br />
WISEMAN EH, SCHREIBER EC, PINSON R Jr.<br />
DOI: 10.1016/0006-2952(64)90190-x PMID: 14222190 [Indexed for MEDLINE]<br />
<br />
[4]. Anesthesiology. 1972 May;36(5):519-20. doi: 10.1097/00000542-197205000-00025.<br />
The effects of benzquinamide and prochlorperazine, separately and combined, on the human respiratory center.<br />
Steen SN, Yates M.<br />
DOI: 10.1097/00000542-197205000-00025 PMID: 5067296 [Indexed for MEDLINE]<br />
<br />
[5]. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):530-7. doi: 10.1002/cpt1970114530.<br />
Inhibition of apomorphine-induced vomiting by benzquinamide.<br />
Klein RL, Graves CL, Kim YI, Blatnick R.<br />
DOI: 10.1002/cpt1970114530 PMID: 4913868 [Indexed for MEDLINE]
|
